SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-14-006638
Filing Date
2014-02-05
Accepted
2014-02-05 12:03:11
Documents
11
Period of Report
2013-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q a14-3238_110q.htm 10-Q 334143
2 EX-31.1 a14-3238_1ex31d1.htm EX-31.1 10554
3 EX-31.2 a14-3238_1ex31d2.htm EX-31.2 10579
4 EX-32.1 a14-3238_1ex32d1.htm EX-32.1 4544
5 EX-32.2 a14-3238_1ex32d2.htm EX-32.2 4585
  Complete submission text file 0001104659-14-006638.txt   2482585

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT cont-20131231.xml EX-101.INS 227088
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cont-20131231.xsd EX-101.SCH 25049
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cont-20131231_cal.xml EX-101.CAL 20997
9 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT cont-20131231_lab.xml EX-101.LAB 370382
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cont-20131231_pre.xml EX-101.PRE 179804
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cont-20131231_def.xml EX-101.DEF 101977
Mailing Address 420 LEXINGTON AVENUE SUITE 2012 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2012 NEW YORK NY 10170 212-297-0020
ContraVir Pharmaceuticals, Inc. (Filer) CIK: 0001583771 (see all company filings)

IRS No.: 462783806 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55020 | Film No.: 14575207
SIC: 2834 Pharmaceutical Preparations